NCT04319328View on ClinicalTrials.gov

Is Cefazolin, Ceftazidime and Ciprofloxacin Dosing Optimal in Hemodialysis Patients?

CompletedOBSERVATIONAL
Enrollment

40

Participants

Timeline

Start Date

October 18, 2019

Primary Completion Date

April 30, 2024

Study Completion Date

April 30, 2024

Conditions
Hemodialysis ComplicationInfectious DiseaseEnd Stage Renal Disease
Interventions
DRUG

Cefazolin

Non-interventional pharmacokinetic evaluation

DRUG

Ceftazidime

Non-interventional pharmacokinetic evaluation

Trial Locations (2)

R2H 2A6

Saint Boniface Hospital, Outpatient Hemodialysis Unit, Winnipeg

R3E 0T5

College of Pharmacy, University of Manitoba, Winnipeg

All Listed Sponsors
collaborator

The Kidney Foundation of Canada

OTHER

lead

University of Manitoba

OTHER

NCT04319328 - Is Cefazolin, Ceftazidime and Ciprofloxacin Dosing Optimal in Hemodialysis Patients? | Biotech Hunter | Biotech Hunter